Sangamo Therapeutics Inc (NASDAQ:SGMO) CFO Kathy Yi sold 5,000 shares of the stock in a transaction on Friday, March 15th. The stock was sold at an average price of $10.00, for a total transaction of $50,000.00. Following the transaction, the chief financial officer now directly owns 30,512 shares in the company, valued at $305,120. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Kathy Yi also recently made the following trade(s):
- On Friday, March 1st, Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock. The stock was sold at an average price of $10.00, for a total transaction of $50,000.00.
- On Tuesday, January 15th, Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock. The stock was sold at an average price of $11.04, for a total transaction of $55,200.00.
Sangamo Therapeutics stock opened at $9.74 on Wednesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.23 and a current ratio of 5.23. The firm has a market cap of $992.02 million, a price-to-earnings ratio of -13.91 and a beta of 2.83. Sangamo Therapeutics Inc has a one year low of $6.26 and a one year high of $24.45.
Several equities analysts have commented on SGMO shares. BidaskClub raised shares of Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, January 9th. ValuEngine downgraded shares of Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, January 2nd. Zacks Investment Research downgraded shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 18th. Finally, Wedbush set a $10.00 target price on shares of Sangamo Therapeutics and gave the stock a “hold” rating in a research report on Sunday, March 10th. One research analyst has rated the stock with a sell rating, four have given a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $16.40.
TRADEMARK VIOLATION NOTICE: “Insider Selling: Sangamo Therapeutics Inc (SGMO) CFO Sells 5,000 Shares of Stock” was posted by WKRB News and is the sole property of of WKRB News. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.wkrb13.com/2019/03/20/insider-selling-sangamo-therapeutics-inc-sgmo-cfo-sells-5000-shares-of-stock-2.html.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Read More: How to calculate compound interest
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.